Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.6 EUR | 0.00% | +4.09% | +30.84% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.84% | 129M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.64% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- OSE Stock
- News OSE Immunotherapeutics
- OSE Immunotherapeutics Enrolls First Patient in Phase 2 Study Of Non-Small Cell Lung Cancer Treatment